Dr. Eric Fossel recieved his PhD from Harvard University with a degree in Chemistry. He has been an Instructor and Associate Professor at Harvard in the years 1970-1977. He had previously been CEO and Founder of Strategic Science & Technologies, a company in Phase 3 of clinical trials. He has also been CEO and Founder of ImmunoOncolytics as well as a CoFounder of Novilla Pharmaceuticals that is in Phase 1 of their clinical trials. Closely related work: 1. Fossel E.T., Zanella C.L., Fletcher J.G., Hui K.K.S.. Cell Death Induced by Peroxidized Low- Density Lipoprotein: Endopepsis. Cancer Research. 1994; 54(5):1240-1248. Available from: http://www.scopus.com/inward/record.url?eid=2-s2.0-0028220687&partnerID=MN8TOARS eid: 2-s2.0-0028220687 2. McDonagh J, Fossel E, Kradin R, Dubinett S, Laposata M, Hallaq Y. Effects of tumor necrosis factor-alpha on peroxidation of plasma lipoprotein lipids in experimental animals and patients. Blood. 1992 December 15; 80(12):3217-3226. Available from: https://ashpublications.org/blood/article/80/12/3217/169629/Effects-of-tumor-necrosisfactoralpha- on DOI: 10.1182/blood.V80.12.3217.3217 3. Fossel E, Fletcher J, McDonagh J, Hui K. Selective Cytotoxicity of Low-Density Lipoprotein to Helper T Cells of Cutaneous T-Cell Lymphoma After Photoperoxidation With 8-Methoxypsoralen. JNCI Journal of the National Cancer Institute. 1991 September 18; 83(18):1316-1321. Available from: https://academic.oup.com/jnci/articlelookup/ doi/10.1093/jnci/83.18.1316 DOI: 10.1093/jnci/83.18.1316